RCT of PR-ESSENCE - a Problem Solving Model for Youth With Challenging Behavior in Special (SiS) Treatment Homes

Sponsor
Göteborg University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04505072
Collaborator
(none)
70
1
2
46.7
1.5

Study Details

Study Description

Brief Summary

Randomized controlled trial of PR-ESSENCE treatment for youth with challenging behavior in two youth treatment homes, including 60-70 youth. Inclusion criteria: Youth aged 12-17 years, staying at least 3 months at the home, with intellectual function in the normal range according to WISC-test and clinical judgment, and exhibiting significant problem behaviors as measured by Broset Violence Checklist (BVC). Subjects are randomized to 10 weeks of PR-ESSENCE treatment or to the control condition "treatment as usual". After the control period, the control group will receive 10 weeks of PR-ESSENCE treatment. Outcome is assessed at baseline, post-treatment/control period, and 3-6 months post-treatment (at the time when the youth is planned to move from the home) with global assessments of problem severity and improvement by blinded rater (CGI-I, CGI-S), ratings of SNAP-IV (ADHD and oppositional symptoms), ECBI (behavior problems) and RPQ (relation problems) by the youth's contact person, and self-ratings of psychiatric symptoms and self-concept with Becks Youth Inventories. BVC ratings are also made daily by contact persons and teachers during the whole study.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: PR-ESSENCE
  • Behavioral: Treatment as usual
N/A

Detailed Description

PR-ESSENCE is a problem-solving training program developed by our research team, inspired by Dr Greene´s model "Collaborative and Proactive Solutions (CPS)". We recently completed an RCT with PR-ESSENCE at the Gillberg Centre, Gothenburg University, including 108 children and adolescents who had complex neurodevelopmental disorders such as autism, ADHD, ODD, Tourette, learning difficulties etc and challenging behaviors. The study showed significant global improvements in behavior problems with a large effect size.

The PR-ESSENCE model is designed to train and develop mutual problem solving strategies for children and adolescents with neurodevelopmental disorders (ESSENCE, an umbrella term coined by Gillberg 2010 = Early Symptomatic Syndromes Eliciting Neuropsychiatric Clinical Examinations, which puts focus on the considerable overlap several of these syndromes have). Many youth who are placed in youth treatment homes due to challenging and risk-taking behaviors have been shown to have ESSENCE impairments.

The present study is a randomized controlled trial of PR-ESSENCE treatment for youth with challenging behavior in two youth treatment homes in southwestern Sweden, Bjorkbacken (girls) and Nereby (boys). We plan to include 60-70 youth. Inclusion criteria: Youth aged 12-17 years, staying at least 3 months at the home, with intellectual function in the normal range according to WISC-test and clinical judgment, and exhibiting significant problem behaviors as measured by Broset Violence Checklist (BVC). Exclusion criteria: Intellectual disability, bipolar syndrome, psychosis, substance use, or other unstable psychiatric or medical condition which would make study participation unsuitable. Psychoactive medication is allowed if stable at least one month before baseline, and during the trial.

At baseline a medical and neuropsychiatric history is taken by psychologist and physician (a standard assessment done for all youth placed at the homes), including rating of history of risk behaviors with Youth Level of Service/Case Management Inventory (YLS/CMI), and a DSM-5-diagnostic screening (DSM-5-CCSM) for psychiatric symptoms. Intellectual level will be tested with WISC-V. The participants will do self-ratings of psychiatric symptoms and self-concept with Becks Youth Inventories. The therapists interview parents/carers about history of neuropsychiatric symptoms with the A-TAC-interview.

Subjects are randomized to 10 weeks of PR-ESSENCE treatment or to the control condition "treatment as usual". After the control period, the control group will also receive 10 weeks of PR-ESSENCE treatment. Outcome is assessed at baseline, post treatment/control period, and 3-6 months post-treatment (at the time when the youth is planned to move from the home) with global assessments of problem severity and improvement by blinded independent rater (CGI-I, CGI-S), ratings of SNAP-IV (ADHD and oppositional symptoms), ECBI (behavior problems) and RPQ (relation problems) by the youth's contact person, and self-ratings of psychiatric symptoms and self-concept with Becks Youth Inventories. BVC ratings are made daily by contact persons and teachers during the whole study. During treatment, therapists rate every week with a Problem Rating Scale how many problem situations are completely or partly solved.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized Controlled TrialRandomized Controlled Trial
Masking:
Single (Outcomes Assessor)
Masking Description:
Primary outcome assessed by blinded rater
Primary Purpose:
Treatment
Official Title:
Randomized Controlled Study of PR-ESSENCE - a Problem Solving Model for Youth With Challenging Behavior in Special (SiS) Treatment Homes
Actual Study Start Date :
Feb 10, 2021
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: PR-ESSENCE treatment

PR-ESSENCE treatment 10 weeks

Behavioral: PR-ESSENCE
Manual-based training of mutual problem-solving

Active Comparator: Control

Treatment as usual 10 weeks

Behavioral: Treatment as usual
General support in daily structure and activities that is given to all youth staying at the treatment homes

Outcome Measures

Primary Outcome Measures

  1. Clinical Global Impression- Improvement (CGI-I) [10 weeks, change]

    Global rating of improvement by blinded rater based on all available information, score range 1-7, lower is better

Secondary Outcome Measures

  1. Clinical Global Impression- Severity (CGI-S) [10 weeks, change]

    Global rating of symptom severity by blinded rater based on all available information, score range 1-7, lower is better

  2. Broset Violence Checklist (BVC) [10 weeks, change]

    Measures problem behaviors frequency/intensity, score range 0-36 per day, lower is better

  3. SNAP-IV [10 weeks, change]

    Measures ADHD and Oppositional Defiant symptoms, score range ADHD 0-54, ODD 24, lower is better

  4. Eyberg Child Behavior Inventory (ECBI) [10 weeks, change]

    Measures behavior problems frequency/intensity, score range 36-252, lower is better

  5. Relationship Problems Questionnaire (RPQ) [10 weeks, change]

    Measures relationship problems, score range 0-30, lower is better

Eligibility Criteria

Criteria

Ages Eligible for Study:
12 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Youth with problem behaviors, placed for at least 3 months in the youth treatment homes Nereby (boys) and Bjorkbacken (girls).

  2. Age 12-17 years

  3. Intellectual function in the normal range according to WISC-test and clinical judgment

  4. Problem behavior score of at least 5 points in one week on the Broset Violence Checklist (BVC). Score is measured during 2 weeks before screening

  5. Medium to high-risk score on the YLS/CMI behavior problem domain 7

  6. Psychotropic medication is allowed if stable during one month before baseline and during the randomized period of the trial

Exclusion Criteria:
  1. Intellectual disability, bipolar syndrome, psychosis, substance use, or other unstable psychiatric or medical condition that would make study participation unsuitable

Contacts and Locations

Locations

Site City State Country Postal Code
1 Gillberg Neuropsychiatry Centre Gothenburg V. Gotaland Sweden 411 19

Sponsors and Collaborators

  • Göteborg University

Investigators

  • Study Chair: Christopher Gillberg, Professor, Gillberg Neuropsychiatry Centre, Gothenburg University

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Göteborg University
ClinicalTrials.gov Identifier:
NCT04505072
Other Study ID Numbers:
  • GNC SiS PR-ESSENCE
First Posted:
Aug 7, 2020
Last Update Posted:
Aug 16, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2022